



Schering-Plough Animal Health Corporation  
1095 Morris Ave  
Union, NJ 07083

## MATERIAL SAFETY DATA SHEET

Schering-Plough urges each user or recipient of this MSDS to read the entire data sheet to become aware of the hazards associated with this material.

### SECTION 1. IDENTIFICATION OF SUBSTANCE AND CONTACT INFORMATION

**MSDS NAME:** Nuflor 2.3% Concentrate Solution

**SYNONYM(S):** Nuflor Drinking Water Concentrate for Swine

**MSDS NUMBER:** SP001427

**EMERGENCY NUMBER(S):** Schering-Plough Security Control Center (908) 820-6921 (24 hours)

Transportation Emergencies -  
CHEMTREC: (800) 424-9300 (Inside Continental USA)  
(703) 527-3887 (Outside Continental USA)

Animal Health Technical Services:  
For Animal Adverse Events: Small Animals and Horses: (800) 224-5318  
For Animal Adverse Events: Livestock: (800) 211-3573  
For Animal Adverse Events: Poultry: (800) 219-9286  
Rocky Mountain Poison Center (For Human Exposure):  
(303) 595-4869

**INFORMATION:** Animal Health Technical Services:  
For Small Animals and Horses: (800) 224-5318  
For Livestock: (800) 211-3573  
For Poultry: (800) 219-9286

**SCHERING-PLOUGH MSDS HELPLINE:** (800) 770-8878 (US and Canada)  
(908) 629-3657 (Worldwide)  
Monday to Friday, 9am to 5pm (US Eastern Time)

### SECTION 2. COMPOSITION AND INFORMATION ON INGREDIENTS

**PRODUCT USE:** Veterinary product

**CHEMICAL FORMULA:** Mixture.

The formulation for this product is proprietary information. Only hazardous ingredients in concentrations of 1% or greater and/or carcinogenic ingredients in concentrations of 0.1% or greater are listed in the Chemical Composition table. Active ingredients in any concentration are listed. For additional information about carcinogenic ingredients see Section 3.

#### CHEMICAL COMPOSITION

CHEMICAL NAME	CAS NUMBER	PERCENT
Florfenicol	73231-34-2	2.3
Polyethylene Glycol	25322-68-3	>90

**ADDITIONAL INFORMATION:** This MSDS is written to provide health and safety information for individuals who will be handling the final product formulation during research, manufacturing, and distribution. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate MSDS for each ingredient. Refer to the package insert or product label for handling guidance for the consumer.

### SECTION 3. HAZARDS IDENTIFICATION

Nuflor 2.3% Concentrate Solution  
Latest Revision Date: 06-Feb-2004

NUFLOR ORAL 2.3% CONCENTRATE

#020130

2/6/04

Print date: 06-Feb-2004

Page 1 of 6

## EMERGENCY OVERVIEW

Clear, Colorless  
Liquid  
Odor unknown

May cause allergic reactions in susceptible individuals.

Harmful to aquatic organisms.  
May cause long-term adverse effects in the aquatic environment.

### POTENTIAL HEALTH EFFECTS:

The following summary is based upon available information about the individual ingredients of the mixture, or of the expected properties of the mixture.

This product is not for use in humans. Clinical effects in humans have not been determined.

Florfenicol, the active ingredient in this product, is a broad spectrum antibiotic used in veterinary products. Florfenicol may cause allergic reactions in susceptible individuals. Based on animal studies, florfenicol may cause slight eye irritation, constipation, changes in blood cell counts, changes in stool, or liver effects. It may also cause developmental effects or effects to male reproductive organs.

Acute exposure to polyethylene glycol may cause slight eye or skin irritation, abnormal taste, gas, nausea, vomiting, diarrhea, irregular heartbeat, low blood pressure, or fluid in the lungs. Repeated exposure of polyethylene glycol to damaged skin has been reported to cause kidney failure and necrosis.

### LISTED CARCINOGENS

Not listed as a carcinogen by OSHA, IARC, NTP or ACGIH.

## SECTION 4. FIRST AID MEASURES

<b>INHALATION:</b>	Remove to fresh air. If any trouble breathing, get immediate medical attention. Administer artificial respiration if breathing has ceased. If irritation or symptoms occur or persist, consult a physician.
<b>SKIN CONTACT:</b>	In case of skin contact, while wearing protective gloves, carefully remove any contaminated clothing, including shoes, and wash skin thoroughly with soap and water. If irritation or symptoms occur or persist, consult a physician.
<b>EYE CONTACT:</b>	In case of eye contact, immediately rinse eyes thoroughly with plenty of water. If wearing contact lenses, remove only after initial rinse, and continue rinsing eyes for at least 15 minutes. If irritation occurs or persists, consult a physician.
<b>INGESTION:</b>	Rinse mouth and drink a glass of water. Do not induce vomiting. If symptoms persist, consult a physician.
<b>NOTE TO PHYSICIAN:</b>	This product contains florfenicol, a broad spectrum antibiotic which may cause allergic reactions in susceptible individuals.

## SECTION 5. FIRE FIGHTING MEASURES

### FLAMMABILITY DATA:

FLASH POINT: 196-213 deg C ( 385-415 deg F) (polyethylene glycol) METHOD: Cleveland open cup

### SPECIAL FIRE FIGHTING PROCEDURES:

Wear full protective clothing and self-contained breathing apparatus (SCBA).

### SUITABLE EXTINGUISHING MEDIA:

Carbon dioxide (CO<sub>2</sub>), extinguishing powder or water spray.

See Section 9 for Physical and Chemical Properties.

## SECTION 6. ACCIDENTAL RELEASE MEASURES

Nuflor 2.3% Concentrate Solution  
Latest Revision Date: 06-Feb-2004

Print date: 06-Feb-2004

**PERSONAL PRECAUTIONS:**

Keep personnel away from the clean-up area. Wear appropriate personal protective equipment as specified in Section 8.

**SPILL RESPONSE / CLEANUP:**

All spills should be handled according to site requirements and based on precautions cited in the MSDS. In the case of liquids, use proper absorbent materials. In manufacturing and large-scale operations, HEPA vacuuming prior to wet mopping or cleaning is required.

**ENVIRONMENTAL PRECAUTIONS:**

This product is harmful to fish and/or aquatic organisms. Do not allow product to reach ground water, water course, sewage or drainage systems.

See Sections 9 and 10 for additional physical, chemical, and hazard information.

**SECTION 7. HANDLING AND STORAGE**

**HANDLING:**

Keep containers adequately sealed during material transfer, transport, or when not in use.

Appropriate handling of this material is dependent on many factors, including physical form, duration and frequency of process or task, and effectiveness of engineering controls. Site-specific risk assessments should be conducted to determine the feasibility and the appropriateness of all exposure control measures. See Section 8 (Exposure Controls) for additional guidance.

**STORAGE:**

Store between 2 and 25 deg C (36 to 77 deg F).

See Section 8 for exposure controls and additional safe handling information.

**SECTION 8. EXPOSURE CONTROLS AND PERSONAL PROTECTION**

The following guidance applies to the handling of the active ingredient(s) in this formulation.

**S-P OCCUPATIONAL EXPOSURE GUIDELINE (OEG):**

Schering-Plough Corporation has established an Occupational Exposure Guideline (OEG) of 180 mcg/m<sup>3</sup> (8-hr TWA) for Florfenicol. Consult your site safety professional for additional guidance.

**EXPOSURE CONTROLS:**

The health hazard risks of handling this material are dependent on many factors, including physical form, duration and frequency of process or task, and effectiveness of engineering controls. Site-specific risk assessments should be conducted to determine the feasibility and the appropriateness of all exposure control measures. Exposure controls for normal operating or routine procedures follow a tiered strategy. Engineering controls are the preferred means of long-term or permanent exposure control. If engineering controls are not feasible, substitution of approved materials or appropriate use of personal protective equipment (PPE) may be considered as alternative control measures. However, PPE should not be used as a method of permanent or long-term exposure control. Exposure controls for non-routine operations must be evaluated and addressed as part of the site-specific risk assessment.

**RECOMMENDED PERSONAL PROTECTIVE EQUIPMENT (PPE):**

- Respiratory Protection: Respirators are not normally required; however, appropriate respiratory protection may be required in situations where exposure (e.g. spills, process upsets, or non-routine maintenance) may exceed any available recommended exposure limit. Consult your site safety staff for guidance.  
  
In manufacturing and large-scale operations, powered air purifying respirators (PAPRs) or positive-pressure air supplied respirators with full-face coverage may be required dependent on the level of exposure. Appropriate respiratory protection is required in situations where exposure (e.g. spills, process upsets, or non-routine maintenance) may exceed any available recommended exposure limit. Consult your site safety staff for guidance.
- Skin Protection: Gloves that provide an appropriate barrier to the skin are recommended if there is potential for contact with this material. Consult your site safety staff for guidance.
- Eye Protection: Safety glasses with side shields. Use of goggles or full face protection may be required if there is potential for contact with this material. Consult your site safety staff for guidance.
- Body Protection: In small scale or laboratory operations, lab coats or other equivalent protective clothing is required. In large-scale or manufacturing operations, lab coats or other equivalent protective clothing is required.

**EXPOSURE LIMIT VALUES**

See Schering-Plough occupational exposure guideline (OEG) listed above.

## SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

**FORM:** Liquid  
**COLOR:** Clear, Colorless  
**ODOR:** Odor unknown  
**SOLUBILITY:**  
Water: Not determined

See Section 5 for flammability/explosivity information.

## SECTION 10. STABILITY AND REACTIVITY

**STABILITY/ REACTIVITY:**  
Stable under normal conditions.

**INCOMPATIBLE MATERIALS / CONDITIONS TO AVOID:**  
Do not operate chlorinators while administering medication. Do not use or store this product in galvanized metal watering systems or containers.

## SECTION 11. TOXICOLOGICAL INFORMATION

The information presented below pertains to the following individual ingredients in this formulation, unless indicated otherwise.

### ACUTE TOXICITY DATA

#### INHALATION:

Rats exposed to florfenicol for 4 hours showed dry rales, anogenital staining, secretory discharge, soft stool, and decreased body weights. These effects were seen immediately or up to one-week post exposure. Some effects did not resolve by study termination. The inhalation LC50 (4 hr) was >0.28 mg/L in rats.

No mortalities were reported in rats following a 4-hour exposure to polyethylene glycol generated at 170 deg C.

#### SKIN:

Florfenicol was not irritating to rabbit skin (PII = 0)

Polyethylene glycols (200-9000): Dermal LD50: >20 g/kg (unspecified species).  
Polyethylene glycol was not irritating to the skin of rabbits and guinea pigs.  
Polyethylene glycol was not irritating in a human patch test.

#### EYE:

Florfenicol was slightly irritating to the eyes of rabbits.  
Polyethylene glycols did not produce appreciable eye irritation in rabbits.

#### ORAL:

Florfenicol: Oral LD50: >2000 mg/kg (rat, mouse).  
Dogs (one animal/sex) were administered successive oral doses of florfenicol that ranged from 160 to 1280 mg/kg. No clinical effects occurred at doses as high as 640 mg/kg. At 640 mg/kg, the only female died from inhalation of vomitus. Vomiting or soft stool occurred at 640 to 1280 mg/kg.

Polyethylene glycol 300: Oral LD50: 17 to 39 g/kg (rat, mouse, guinea pig, rabbit)

#### SENSITIZATION:

Florfenicol was not a skin sensitizer in guinea pigs.

Polyethylene glycols did not produce skin sensitization in guinea pigs.

### REPEAT DOSE TOXICITY DATA

#### SUBCHRONIC / CHRONIC TOXICITY:

Nuflor 2.3% Oral Concentrate was administered in the drinking water of swine at dosages as high as 4000 mg/gallon (0.0024% florfenicol active) for periods of as long as 16 days. Effects included decreased body weight, decreased food and water consumption, changes in serum electrolytes and proteins, increased lymphocyte count, darkened stool, constipation, compacted stool, and increased liver and heart weights. At the highest dosage, kidney weight and urine specific gravity were increased. Periannal irritation, inflammation, and rectal eversion were observed in efficacy studies at low dosages; these effects were reversible.

Florfenicol was administered orally to dogs, rats, and mice at dosages as high as 100 to 400 mg/kg/day for up to 13 weeks. Effects including decreased body weight, changes in liver weight or liver enzyme levels, changes in testicular weight, testicular atrophy, decreased white blood cell counts, and decreased hemoglobin levels were observed at high dosages. Cellular changes in the liver or lymph nodes of rats and mice, and histopathologic changes in the brain and spinal cord of dogs were also noted at these high dosages. Although some effects were reversible after a 4-week withdrawal from treatment, testicular effects in rats persisted. Intramuscular injections of 45 mg/kg of florfenicol in swine produced diarrhea, injection site lesions, decreased body weight, decreased food and water consumption, changes in serum electrolytes and proteins, decreased red blood cell and white blood cell counts, decreased spleen weight, and decreased kidney weight.

In 52-week oral toxicity studies in dogs and rats, high dosages of florfenicol (12 and 48 mg/kg/day, respectively) increased liver weight and produced cellular changes in the gall bladder of dogs. In rats, florfenicol at the high dosage reduced body weight gain, reduced testicular weight, induced changes in hematologic and clinical chemistry parameters, and increased the incidence of testicular tubular atrophy. In two-year chronic studies in mice and rats, florfenicol caused similar effects as those observed in other long-term studies including reduced body weight gain, reduced red blood cell count, reduced hemoglobin levels, and testicular effects such as small testes, tubular atrophy and aspermatogenesis in both the high dosage rats (48 mg/kg/day) and mice (200 mg/kg/day).

Polyethylene glycol 400 produced no adverse effects in dogs and rats fed 2% in the diet for one or two years, respectively. Repeated dermal exposure to polyethylene glycol 300 for an eight-week period had no effect on mice. Repeated inhalation exposure to 1008 mg/m<sup>3</sup> of a higher molecular weight polyethylene glycol increased lung weight, and also produced reversible increases in neutrophil counts in male rats.

#### REPRODUCTIVE / DEVELOPMENTAL TOXICITY:

In a two-generation reproductive study, oral administration as high as 12 mg/kg/day of florfenicol reduced epididymal weights, decreased pup survival, and reduced lactation index in rats [NOAEL: 3 mg/kg/day].

There was no evidence of teratogenicity in rats administered florfenicol at dosages of 4, 12 or 40 mg/kg/day. Slight maternal toxicity, evidenced by decreased food and water consumption, was observed above 4 mg/kg/day. At 40 mg/kg/day, an increased incidence of delayed ossification and decreased fetal weight occurred. The NOAEL for maternal and fetal toxicity in rats was determined to be 4 mg florfenicol/kg/day.

Two teratogenicity studies were performed in mice. In the first study, the mice were administered florfenicol at dosages of 40, 120, or 400 mg/kg by gavage on days 6-15 of gestation. Florfenicol produced embryoletality at the 400 mg/kg/day dose level, which was evidenced by the high incidence of intrauterine deaths. Significant decreases in mean fetal body weight, soft tissue defects, and retarded skeletal ossification were also observed at 400 mg/kg/day. Skeletal ossification was less pronounced, in a dose-related fashion, at the lower doses tested (40 and 120 mg/kg/day). A developmental NOAEL could not be determined for these data [NOAEL for maternal: 120 mg/kg]. In the second teratogenicity study, florfenicol was retested at lower administered dosages of 1, 3, or 60 mg/kg/day. Maternal effects were limited to a slight increase in water consumption at the 60 mg/kg/day dose. There was no evidence of any adverse effects on the embryo/fetus at doses as high as 60 mg/kg/day in this study. However, based upon the retarded skeletal ossification effects observed in the first study at 40 mg/kg/day the NOAEL for the two studies combined was determined to be between 3 and 40 mg/kg/day.

Polyethylene glycol 200 was developmentally toxic in mice, causing malformations and other fetotoxicity, but elicited no similar response in rats at higher doses.

#### MUTAGENICITY / GENOTOXICITY:

Florfenicol was negative in a bacterial mutagenicity study (Ames), a mammalian mutagenicity study (mouse lymphoma), a bone marrow micronucleus assay, an in vitro chromosomal aberration assay in CHO cells, a cytogenetics assay in bone marrow, and an unscheduled DNA synthesis assay in rat hepatocytes.

Polyethylene glycol was negative in a bacterial mutagenicity study (Ames), results were inconclusive in a bacterial DNA repair study.

#### CARCINOGENICITY:

This material has not been evaluated for carcinogenicity.

Florfenicol was not carcinogenic in a 2-year study in rats administered dosages up to 48 mg/kg/day for 5 days a week or in mice at dosages up to 200 mg/kg/day for 5 days per week.

## SECTION 12. ECOLOGICAL INFORMATION

This information presented below pertains to the following ingredient(s) and does not apply to the final product or its formulation(s).

#### ECOTOXICITY DATA

##### INGREDIENT ECOTOXICITY

Florfenicol: 96-hr LC50 (bluegill): >830 mg/L  
Florfenicol: 96-hr LC50 (trout): >780 mg/L  
Florfenicol: 48-hr EC50 (daphnid): >330 mg/L  
Florfenicol: Algae maximum cell density: MIC = 1.5 mg/L  
Florfenicol: Algae maximum growth rate: MIC >2.9 mg/L

#### ENVIRONMENTAL DATA

Nuflor 2.3% Concentrate Solution  
Latest Revision Date: 06-Feb-2004

Print date: 06-Feb-2004

**OTHER INGREDIENT ENVIRONMENTAL DATA:**

Florfenicol is not readily biodegradable but there is evidence of inherent biodegradability.

**SECTION 13. DISPOSAL CONSIDERATIONS**
**MATERIAL WASTE:**

Disposal must be in accordance with applicable federal, state/provincial, and/or local regulations. Incineration is the preferred method of disposal, when appropriate. Operations that involve the crushing or shredding of waste materials or returned goods must be handled to meet the ECG or OEG.

**PACKAGING AND CONTAINERS:**

Disposal must be in accordance with applicable federal, state/provincial, and/or local regulations.

**SPECIAL ENVIRONMENTAL HANDLING PROCEDURES:**

This product contains materials that are harmful to the environment. Do not allow product to reach ground water, water courses, sewage or drainage system.

**SECTION 14. TRANSPORT INFORMATION**

This material is not subject to the transportation regulations of DOT, ICAO, IMO, and the ADR.

**SECTION 15. REGULATORY INFORMATION**
**TSCA LISTING**

CHEMICAL NAME	TSCA
Polyethylene Glycol	Listed

**U.S. STATE REGULATIONS**

CHEMICAL NAME	PARTK	MNRTK	MIRTK	ILRTK	LARTK	RIRTK
Polyethylene Glycol		Listed.				

**SECTION 16. OTHER INFORMATION**

Although reasonable care has been taken in the preparation of this document, we extend no warranties and make no representations as to the accuracy or completeness of the information contained therein, and assume no responsibility regarding the suitability of this information for the user's intended purposes or for the consequence of its use. Each individual should make a determination as to the suitability of the information for their particular purpose(s).

**DEPARTMENT ISSUING MSDS:**

Global Safety and Environmental Affairs  
Occupational and Environmental Toxicology  
Schering-Plough Corporation  
1095 Morris Avenue  
Union, NJ 07083 USA

**SCHERING-PLOUGH MSDS HELPLINE:**

(800) 770-8878 (US and Canada)  
(908) 629-3657 (Worldwide)  
Monday to Friday, 9am to 5pm (US Eastern Time)

**MSDS CREATION DATE:**

08-Dec-2003

**SUPERSEDES DATE:**

08-Dec-2003